GlassScriptPhysician profile
Daniel L Kinsey
NPI 1306880109
$3,493.34
in general payments reported to CMS, 2019-2025
17 companies · $1,993 in 2025
The $1,993 reported for 2025 was more than what 94% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $73.22 · 2021: $124 · 2022: $135 · 2023: $74.48 · 2024: $990 · 2025: $1,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,897 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,897.19 |
| Education | $160.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $594.18 | 2020-2025 | Rejoyn, Rexulti |
| Alkermes, INC. | $437.68 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $355.06 | 2023-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.93 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $303.24 | 2025 | |
| Axsome Therapeutics, INC. | $284.78 | 2024-2025 | Auvelity |
| Abbvie INC. | $244.40 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $225.61 | 2022-2025 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $207.64 | 2024-2025 | Cobenfy |
| Corium, LLC | $202.57 | 2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $102.12 | 2019-2023 | Abilify Maintena, Rexulti |
| Sunovion Pharmaceuticals INC. | $71.55 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $40.88 | 2022 | |
| Indivior INC. | $38.20 | 2021 | |
| Noven Therapeutics, LLC | $33.54 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $31.56 | 2022 | |
| Neuronetics, INC. | $16.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kinsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.